2,6-dibenzyloxybenzyl alcohol | 25983-52-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2,6-dibenzyloxybenzyl alcohol
• 英文别名: 2,6-Dibenzyloxybenzylalkohol；(2,6-Bis-benzyloxyphenyl)-methanol；[2,6-bis(phenylmethoxy)phenyl]methanol
• CAS: 25983-52-2
• 化学式: C₂₁H₂₀O₃
• 分子量: 320.388
• InChiKey: BTBUEALZFHTTKB-UHFFFAOYSA-N

物化性质

• 沸点：
  490.6±40.0 °C(Predicted)
• 密度：
  1.175±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2,6-dibenzyloxybenzyl alcohol 在 Collins oxidation agent 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 40.0h， 生成 6-benzyloxy-3-methyl-10-p-tolyl-5-deazaflavin
  参考文献：
  名称：

  Asymmetric reduction with 5-deazaflavin. II. Synthesis of some chiral 5-deazaflavin derivatives.

  摘要：

  为了开发功能性仿生辅酶模型，我们制备了一些新型手性 5-脱氮黄素衍生物。我们合成了在 C(6)位具有手性取代基(13)和在 C(5)位具有手性三级不对称碳中心的 5-脱氮黄素衍生物（15a、b、17a、b 和 18a、b），并取得了相当令人满意的收率。为了研究由此获得的模型的效率，我们用 15a、b 对苯甲酰甲酸乙酯进行了不对称还原的初步实验，结果发现不对称诱导的程度适中或较低。

  DOI：

  10.1248/cpb.38.312
• 作为产物：
  描述：

  2,6-二羟基苯甲酸 在 lithium aluminium tetrahydride 、 18-冠醚-6 、 potassium carbonate 作用下， 以 乙醚 、 丙酮 为溶剂， 生成 2,6-dibenzyloxybenzyl alcohol
  参考文献：
  名称：

  Chiral dendrimers with backfolding wedges

  摘要：

  这种新的构建策略在一种手性树枝状聚合物的合成和光电特性中得到了应用。

  DOI：

  10.1039/a708158h

文献信息

• Synthesis and Fluorescence Properties of Selectively Metallated Diporphyrins with Electron-Accepting Moieties
  作者：Toshi Nagata

  DOI：10.1246/bcsj.64.3005

  日期：1991.10

  Synthesis of selectively metallated diporphyrins with electron-accepting moieties is described. Steady-state fluorescence spectra of these compounds snowed substantial quenching of the fluorescence of the free-base porphyrin. A possible “superexchange” mechanism of long-range electron transfer is discussed.

  文中描述了带有电子受体基团的金属选择性络合二卟啉的合成方法。这些化合物的稳态荧光光谱显示，自由基卟啉的荧光显著淬灭。文章讨论了一种可能的“超交换”机制，即长程电子转移机制。
• Chiral dendrimers with backfolding wedges
  作者：H. W. I. Peerlings、D. C. Trimbach

  DOI：10.1039/a708158h

  日期：——

  Dendritic wedges with a substitution pattern that forces the growth inwards are introduced and the use of this new building strategy is exemplified in the synthesis and chiroptical properties of a chiral dendrimer.

  这种新的构建策略在一种手性树枝状聚合物的合成和光电特性中得到了应用。
• Organic compounds
  申请人：Novartis AG

  公开号：US08084448B2

  公开（公告）日：2011-12-27

  Compounds of the formula are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat and/or prevent cancer, osteoporosis, musculoskeletal, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.

  公式为的化合物是蛋白酪氨酸磷酸酶（PTPase）的抑制剂，因此可用于治疗PTPase活性介导的疾病。本发明的化合物也可用作其他酶的抑制剂，这些酶具有磷酸酪氨酸结合区域，如SH2结构域。因此，公式（I）的化合物可用于预防和/或治疗与肥胖、葡萄糖耐受性、糖尿病、高血压和大、小血管缺血性疾病相关的胰岛素抵抗，以及伴随2型糖尿病的情况，包括高脂血症、高三酰甘油血症、动脉粥样硬化、血管再狭窄、肠易激综合征、胰腺炎、脂肪细胞肿瘤和脂肪肉瘤、脂质代谢异常和其他表现为胰岛素抵抗的疾病。此外，本发明的化合物可用于治疗和/或预防癌症、骨质疏松症、肌肉骨骼、神经退行性和传染性疾病，以及涉及炎症和免疫系统的疾病。
• ORGANIC COMPOUNDS
  申请人：Neubert Alan

  公开号：US20090181928A1

  公开（公告）日：2009-07-16

  Compounds of the formula are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat and/or prevent cancer, osteoporosis, musculoskeletal, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.

  公式的化合物是蛋白酪氨酸磷酸酶（PTPases）的抑制剂，因此可用于治疗由PTPase活性介导的疾病。本发明的化合物也可用作其他酶的抑制剂，这些酶具有磷酸酪氨酸结合区域，如SH2结构域。因此，公式（I）的化合物可用于预防和/或治疗与肥胖、葡萄糖不耐受、糖尿病、高血压以及大、小血管缺血性疾病有关的胰岛素抵抗。这些疾病包括高脂血症、高三酰甘油血症、动脉粥样硬化、血管再狭窄、肠易激综合征、胰腺炎、脂肪细胞肿瘤和脂肪肉瘤等癌症，以及其他显示胰岛素抵抗的疾病。此外，本发明的化合物可用于治疗和/或预防癌症、骨质疏松症、肌肉骨骼、神经退行性和传染性疾病，以及涉及炎症和免疫系统的疾病。
• Synthesis of porphyrins tailored with eight facially-encumbering groups. An approach to solid-state light-harvesting complexes
  作者：Richard W. Wagner、Jonathan S. Lindsey、Ilona Turowska-Tyrk、W.Robert Scheidt

  DOI：10.1016/s0040-4020(01)89413-8

  日期：——

  Synthetic models of the photosynthetic antenna complexes must achieve long-range 3-dimensional order encompassing a large number of porphyrinic pigments with limited direct contact of the pigments. In order to develop solid-state antenna complexes, we have synthesized porphyrins bearing benzyloxy groups projecting over both faces and optionally also around the periphery of the porphyrin. Routes have been established for prefunctionalizing benzaldehydes with various benzyloxy groups. Reaction of 2,6-bis, 3,5-bis, or 2,4,6-tris(benzyloxy)benzaldehydes with pyrrole via the room temperature two-step one-flask porphyrin reaction provides direct access to the facially-encumbered porphyrins. The benzyloxybenzaldehydes react as efficiently as methoxybenzaldehydes, indicating the utility of the -OCH2- unit for introducing large substituents near the face of the porphyrin. The octakis and dodecakis(benzyloxy)porphyrins exhibit characteristic porphyrin absorption and fluorescence properties in solution. The crystal structure of meso-tetrakis[2,6-bis(2,3 4,5,6-pentafluorobenzyloxy)phenyl] porphyrin has been determined. The pentafluorobenzyloxy substituents provide a cavity on each side of the porphyrin plane which has an approximate cylindrical shape with a diameter of similar to 7.5 Angstrom and a height of greater than or equal to 4.5 Angstrom. The porphyrin core parameters are those obtained for free base derivatives in which the inner hydrogen atoms are ordered. Crystal data: a = 14.759(1) Angstrom, b = 25.519 (2) Angstrom, c = 13.100(1) Angstrom, alpha = 100.04(1), beta = 99.83 (1), gamma = 88.25(1), V = 4767.3 (6) Angstrom(3), all measurements at 127 K, triclinic, space group P-1(-), Z = 2 R(1)(F) = 0.097, for 10020 ''observed'' data, and wR(2)(F-2) = 0.275 for 17761 total unique (all) data.